Inhibiting the TLR4/NF-κB/NLRP3 signaling pathway can induce M2 microglial polarization in patients with AD, which reduces neuroinflammation and improves learning and memory disorders (Cui et al., 2020; Yan et al., 2020). Here, NFKB1 is linked to Alzheimer disease.